Neuromuscular conditions associated with malignant hyperthermia in paediatric patients: A 25-year retrospective study

[1]  N. Voermans,et al.  Compound RYR1 heterozygosity resulting in a complex phenotype of malignant hyperthermia susceptibility and a core myopathy , 2015, Neuromuscular Disorders.

[2]  B. Engelen,et al.  RYR1‐related myopathies: a wide spectrum of phenotypes throughout life , 2015, European journal of neurology.

[3]  B. Engelen,et al.  Fever‐induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene , 2014, Internal medicine journal.

[4]  C. Massey,et al.  Malignant Hyperthermia in Canada: Characteristics of Index Anesthetics in 129 Malignant Hyperthermia Susceptible Probands , 2014, Anesthesia and analgesia.

[5]  J. Mullikin,et al.  Using Exome Data to Identify Malignant Hyperthermia Susceptibility Mutations , 2013, Anesthesiology.

[6]  B. Brandom,et al.  Unexpected MH deaths without exposure to inhalation anesthetics in pediatric patients , 2013, Paediatric anaesthesia.

[7]  M. Theroux,et al.  Core myopathies and malignant hyperthermia susceptibility: a review , 2013, Paediatric anaesthesia.

[8]  M. Tarnopolsky,et al.  Genotype-phenotype correlations in recessive RYR1-related myopathies , 2013, Orphanet Journal of Rare Diseases.

[9]  M. Roberts,et al.  Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis , 2013, Neuromuscular Disorders.

[10]  Jeremy W. Linsley,et al.  Stac3 is a component of the excitation-contraction coupling machinery and mutated in Native American myopathy , 2013, Nature Communications.

[11]  Guohua Li,et al.  Excess comorbidities associated with malignant hyperthermia diagnosis in pediatric hospital discharge records , 2011, Paediatric anaesthesia.

[12]  D. Maclennan,et al.  Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum. , 2011, Biochimica et biophysica acta.

[13]  D. Maclennan,et al.  Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population , 2011, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[14]  Gregory C. Allen,et al.  Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006 , 2010, Anesthesia and analgesia.

[15]  H. Gurnaney,et al.  Section Editor: Peter J. Davis Malignant Hyperthermia and Muscular Dystrophies , 2022 .

[16]  Barbara H. Lang,et al.  Epidemiology of Anesthesia-related Mortality in the United States, 1999–2005 , 2009, Anesthesiology.

[17]  A. E. Rossi,et al.  RyR1 S-Nitrosylation Underlies Environmental Heat Stroke and Sudden Death in Y522S RyR1 Knockin Mice , 2008, Cell.

[18]  B. Bissonnette,et al.  Duchenne muscular dystrophy: an old anesthesia problem revisited , 2007, Paediatric anaesthesia.

[19]  J. Lueck,et al.  Heat‐ and anesthesia‐induced malignant hyperthermia in an RyR1 knock‐in mouse , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  G. Goresky,et al.  Inhalation anesthetics and Duchenne’s Muscular Dystrophy , 1999, Canadian journal of anaesthesia = Journal canadien d'anesthesie.

[21]  A. Localio,et al.  A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility , 1994, Anesthesiology.

[22]  C. Doriguzzi,et al.  Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia , 1993, Nature Genetics.

[23]  F. Couch,et al.  Refined genetic localization for central core disease. , 1993, American journal of human genetics.

[24]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. , 1990, Nature.

[25]  M. Farrall,et al.  Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2 , 1990, Nature.

[26]  M. Phillips,et al.  Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia , 1990, Nature.